Head-to-head evidence
CID-103 vs TJ202
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
CID-103
Developed by CASI Pharmaceuticals, Inc.
NCT04758767 · Phase 1 · completed
All participants received CID-103 with no placebo or comparator arm and no blinding, so the design cannot show whether the antibody works better than another option. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
TJ202
Developed by TJ Biopharma Co., Ltd.
NCT03952091 · Phase 3 · completed
The study randomly assigned 289 participants to TJ202 plus lenalidomide and dexamethasone or to the active comparator regimen, but it was open-label rather than blinded. Its primary endpoint was the clinical measure of progression-free survival; because no results are posted, it is not possible to determine whether this endpoint was met.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CID-103's landscape · TJ202's landscape